Upgrade to SI Premium - Free Trial

RBC Capital on Eli Lilly (LLY): Kelonia acquisition payment 'may appear full,' but strategically justified

April 20, 2026 11:20 AM
RBC Capital analyst Trung Huynh reiterated an Outperform rating and $1,250.00 price target on Eli Lilly (NYSE: LLY)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles